Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01698320 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 364
- Enrollment target
NCT01698320 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 364 participants.
The verdict
NCT01698320, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 364 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance through the life of the device during the study.
Interventions
- DRUG Placebo MDPI
- DRUG Albuterol MDPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01698320
The ClinicalTrials.gov registry entry for NCT01698320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo MDPI is the first listed.
NCT01698320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01698320 about?
NCT01698320 is a clinical study titled "Safety Study of Albuterol Spiromax® in Subjects With Asthma". The purpose of this study is to evaluate the safety of Albuterol Spiromax® over 52 weeks during two dosing periods: (1) a 12-week, double-blind, placebo-controlled QID dosing period followed by (2) a 40-week, open-label PRN dosing period, and to evaluate Albuterol Spiromax® device performance throug...
What is the current status of trial NCT01698320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 364 participants. The study started on 2012-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01698320?
The interventions under investigation include: Placebo MDPI (DRUG), Albuterol MDPI (DRUG).
Who is sponsoring clinical trial NCT01698320?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.